Cheng Liu
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Cheng Liu has a total of 51 co-authors. Here are the top co-authors by number of shared publications:
- Cheng Zhang
State Key Laboratory of Holistic Integrative Management of Gastrointestinal Cancers, Beijing Key Laboratory of Carcinogenesis and Translational Research, Department of Gastrointestinal Oncology, Peking University Cancer Hospital & Institute, Beijing, China
13 shared publications - Dali Han
China National Center for Bioinformation, Beijing Institute of Genomics, Chinese Academy of Sciences 3 Department of Computational Biology, Key Laboratory of RNA Science and Engineering Beijing
13 shared publications - Gehan Xu
Key laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Department of Gastrointestinal Oncology, Peking University Cancer Hospital & Institute, Beijing, China
13 shared publications - Guanghao Liang
China National Center for Bioinformation, Beijing Institute of Genomics, Chinese Academy of Sciences 3 Department of Computational Biology, Key Laboratory of RNA Science and Engineering Beijing
13 shared publications - Jian Li
State Key Laboratory of Holistic Integrative Management of Gastrointestinal Cancers, Beijing Key Laboratory of Carcinogenesis and Translational Research, Department of Gastrointestinal Oncology, Peking University Cancer Hospital & Institute, Beijing, China
13 shared publications - Lin Shen
Department of Gastrointestinal Oncology, Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education, Beijing), Peking University Cancer Hospital and Institute, Beijing, China
13 shared publications
Latest Publications
- Open Access
- 2 January 2026
- Published by American Association for Cancer Research (AACR)
Figure S1 from SPP1 Drives Colorectal Cancer Liver Metastasis and Immunotherapy Resistance by Stimulating CXCL12 Production in Cancer-Associated Fibroblasts
Figure S1 Verification of high-metastasis mouse model and the relationship between SPP1 and clinical features. A-F Results of bright field imaging, migration, and invasion assays for LoVo, LoVo-HM, HCT116 and HCT116-HM cells are presented, n = 3 biologically independent experiments. Scale bar, 50 μm. G-J Representative metastatic livers gross morphology from NOD/SCID mice intrasplenically implanted with LoVo, LoVo-HM, HCT116 or HCT116-HM cells (n = 5 per group). K Western blot analysis of SPP1 protein levels in LoVo, LoVo-HM, HCT116, and HCT116-HM cells, n = 3 biologically independent experiments. L Expression of SPP1 gene in different cancer and normal tissues of TIMER2.0 database. M, N Association of SPP1 expression with OS (M) and DFS (N) in CRC based on TCGA data. O-Q Correlation of SPP1 expression with pathological stage, N stage and T stage in CRC patients. All results are presented as mean ± SEM. The data in M, N were determined by Kaplan–Meier analysis with the log-rank test. P values were determined by two-tailed unpaired Student’s t test (C-F, H, J, P) and one-way ANOVA (O, Q). **P < 0.01, ***P < 0.001.
- 2 January 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S1 from SPP1 Drives Colorectal Cancer Liver Metastasis and Immunotherapy Resistance by Stimulating CXCL12 Production in Cancer-Associated Fibroblasts
Figure S1 Verification of high-metastasis mouse model and the relationship between SPP1 and clinical features. A-F Results of bright field imaging, migration, and invasion assays for LoVo, LoVo-HM, HCT116 and HCT116-HM cells are presented, n = 3 biologically independent experiments. Scale bar, 50 μm. G-J Representative metastatic livers gross morphology from NOD/SCID mice intrasplenically implanted with LoVo, LoVo-HM, HCT116 or HCT116-HM cells (n = 5 per group). K Western blot analysis of SPP1 protein levels in LoVo, LoVo-HM, HCT116, and HCT116-HM cells, n = 3 biologically independent experiments. L Expression of SPP1 gene in different cancer and normal tissues of TIMER2.0 database. M, N Association of SPP1 expression with OS (M) and DFS (N) in CRC based on TCGA data. O-Q Correlation of SPP1 expression with pathological stage, N stage and T stage in CRC patients. All results are presented as mean ± SEM. The data in M, N were determined by Kaplan–Meier analysis with the log-rank test. P values were determined by two-tailed unpaired Student’s t test (C-F, H, J, P) and one-way ANOVA (O, Q). **P < 0.01, ***P < 0.001.
- Open Access
- 2 January 2026
- Published by American Association for Cancer Research (AACR)
Figure S6 from SPP1 Drives Colorectal Cancer Liver Metastasis and Immunotherapy Resistance by Stimulating CXCL12 Production in Cancer-Associated Fibroblasts
Figure S6 Talabostat mesylate reverses the progression of CRLM and synergizes with PD-1 blockade therapy A-C Collagen content assessed by Masson’s trichrome staining, and expression levels of α-SMA and CD8 evaluated by mIHC analysis. D, E Ki-67 and TUNEL staining were performed on PDOX tumor tissues to evaluate cell apoptosis and proliferation. F H&E analysis in tumor tissues from each group. G Flow cytometry validated the engraftment of hCD45+ cells 14 days post implantation in each group of mice (n = 3/group). H Collagen content was assessed using Masson’s trichrome staining, while expression levels of α-SMA and CD8 were evaluated through mIHC analysis. Ki-67 and TUNEL staining were performed on PDX tumor tissues to assess cell apoptosis and proliferation. H&E analysis was conducted on tumor tissues from each group. I, J Collagen content assessed by Masson’s trichrome staining, and expression levels of α-SMA evaluated by IHC analysis. IOD: Integrated Optical Density. K TUNEL staining was performed to evaluate cell apoptosis. All results are presented as mean ± SEM. P values were determined by one-way ANOVA. **P < 0.01, ***P < 0.001.
- 2 January 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S6 from SPP1 Drives Colorectal Cancer Liver Metastasis and Immunotherapy Resistance by Stimulating CXCL12 Production in Cancer-Associated Fibroblasts
Figure S6 Talabostat mesylate reverses the progression of CRLM and synergizes with PD-1 blockade therapy A-C Collagen content assessed by Masson’s trichrome staining, and expression levels of α-SMA and CD8 evaluated by mIHC analysis. D, E Ki-67 and TUNEL staining were performed on PDOX tumor tissues to evaluate cell apoptosis and proliferation. F H&E analysis in tumor tissues from each group. G Flow cytometry validated the engraftment of hCD45+ cells 14 days post implantation in each group of mice (n = 3/group). H Collagen content was assessed using Masson’s trichrome staining, while expression levels of α-SMA and CD8 were evaluated through mIHC analysis. Ki-67 and TUNEL staining were performed on PDX tumor tissues to assess cell apoptosis and proliferation. H&E analysis was conducted on tumor tissues from each group. I, J Collagen content assessed by Masson’s trichrome staining, and expression levels of α-SMA evaluated by IHC analysis. IOD: Integrated Optical Density. K TUNEL staining was performed to evaluate cell apoptosis. All results are presented as mean ± SEM. P values were determined by one-way ANOVA. **P < 0.01, ***P < 0.001.
- Open Access
- 2 January 2026
- Published by American Association for Cancer Research (AACR)
Table S3 from SPP1 Drives Colorectal Cancer Liver Metastasis and Immunotherapy Resistance by Stimulating CXCL12 Production in Cancer-Associated Fibroblasts
Plasma SPP1-stratified demographic features of 156 GC patients treated with ICBs.
- 2 January 2026
- Published by American Association for Cancer Research (AACR)
Open AccessTable S3 from SPP1 Drives Colorectal Cancer Liver Metastasis and Immunotherapy Resistance by Stimulating CXCL12 Production in Cancer-Associated Fibroblasts
Plasma SPP1-stratified demographic features of 156 GC patients treated with ICBs.
- Open Access
- 2 January 2026
- Published by American Association for Cancer Research (AACR)
Figure S8 from SPP1 Drives Colorectal Cancer Liver Metastasis and Immunotherapy Resistance by Stimulating CXCL12 Production in Cancer-Associated Fibroblasts
Figure S8 High plasma SPP1 levels are associated with poor response to immunotherapy in GC patients. A, B Statistical analysis of irOS (A) and irPFS (B) in the SPP1 lower and SPP1 higher groups. C-F Statistical analysis of the best treatment efficacy results in the SPP1 lower and SPP1 higher groups. Data in scatter plots indicate mean ± SEM. ***P < 0.001. Log-rank test (A, B), Student’s t test (C-E), one-way ANOVA (F). CR, Complete Response; PR, Partial Response; PD, Progressive Disease; SD, Stable Disease; irOS, immune-related Overall Survival; irPFS, immune-related Progression-Free Survival; ORR, Objective Response Rate; DCR, Disease Control Rate.
- 2 January 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S8 from SPP1 Drives Colorectal Cancer Liver Metastasis and Immunotherapy Resistance by Stimulating CXCL12 Production in Cancer-Associated Fibroblasts
Figure S8 High plasma SPP1 levels are associated with poor response to immunotherapy in GC patients. A, B Statistical analysis of irOS (A) and irPFS (B) in the SPP1 lower and SPP1 higher groups. C-F Statistical analysis of the best treatment efficacy results in the SPP1 lower and SPP1 higher groups. Data in scatter plots indicate mean ± SEM. ***P < 0.001. Log-rank test (A, B), Student’s t test (C-E), one-way ANOVA (F). CR, Complete Response; PR, Partial Response; PD, Progressive Disease; SD, Stable Disease; irOS, immune-related Overall Survival; irPFS, immune-related Progression-Free Survival; ORR, Objective Response Rate; DCR, Disease Control Rate.
- Open Access
- 2 January 2026
- Published by American Association for Cancer Research (AACR)
Figure S5 from SPP1 Drives Colorectal Cancer Liver Metastasis and Immunotherapy Resistance by Stimulating CXCL12 Production in Cancer-Associated Fibroblasts
Figure S5 SPP1-CD44 interaction activates β-catenin/HIF-1α signaling in CAFs. A GSEA analysis of RNA-seq data from CAFs derived from primary tumors (PT-CAFs) and liver metastases (LM-CAFs) of CRC patients. B qRT-PCR and western blot assessed the knockdown efficiency of si-CTNNB1 in CAFs. C qRT-PCR was used to evaluate the mRNA expression of HIF1A in CAFs with CTNNB1 knockdown (left) or MSAB treatment (right), n = 3 biologically independent experiments. D Western blot analysis was performed to assess the protein expression of HIF-1α in CAFs with CTNNB1 knockdown or MSAB treatment. E qRT-PCR and western blot assessed the knockdown efficiency of si-HIF1A in CAFs. F qRT-PCR was used to measure CD44 mRNA levels in T cells and different kind of CAFs. NAF: normal-associated fibroblasts; PT: primary tumor; LM: liver metastasis, n = 3 biologically independent experiments. G qRT-PCR and western blot assessed the knockdown efficiency of si-CD44 in CAFs. H, I Western blot analysis was conducted to evaluate HIF-1α and β-catenin protein expression in control (si-NC) and CD44 knockdown CAFs, with or without conditional medium from HCT116-HM (H) or LOVO-HM (I). J CAF cells were transfected with si-NC or si-CD44 and subsequently treated with conditioned medium from SPP1-overexpressing HCT116 or LoVo cells. The expression levels of β-catenin and HIF-1α were then assessed by western blot. K Western blot analysis was conducted to evaluate HIF-1α and β-catenin protein expression in control (si-NC) and CD44 knockdown CAFs, with or without rhSPP1 protein (1 µg/mL) treatment. L Nuclear-cytoplasmic fractionation was performed to assess the nuclear translocation of HIF-1α in control (si-NC) and CD44 knockdown CAFs, with or without treatment with rhSPP1 protein (1 µg/mL). Western blot experiments in (A, C, F-J) were repeated three times, the data are representative of three biologically independent experiments. All results are presented as mean ± SEM. P values were determined by two-tailed unpaired Student’s t test (C) and one-way ANOVA (B, E-G). ns, no significant difference, **P < 0.01, ***P < 0.001.
- 2 January 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S5 from SPP1 Drives Colorectal Cancer Liver Metastasis and Immunotherapy Resistance by Stimulating CXCL12 Production in Cancer-Associated Fibroblasts
Figure S5 SPP1-CD44 interaction activates β-catenin/HIF-1α signaling in CAFs. A GSEA analysis of RNA-seq data from CAFs derived from primary tumors (PT-CAFs) and liver metastases (LM-CAFs) of CRC patients. B qRT-PCR and western blot assessed the knockdown efficiency of si-CTNNB1 in CAFs. C qRT-PCR was used to evaluate the mRNA expression of HIF1A in CAFs with CTNNB1 knockdown (left) or MSAB treatment (right), n = 3 biologically independent experiments. D Western blot analysis was performed to assess the protein expression of HIF-1α in CAFs with CTNNB1 knockdown or MSAB treatment. E qRT-PCR and western blot assessed the knockdown efficiency of si-HIF1A in CAFs. F qRT-PCR was used to measure CD44 mRNA levels in T cells and different kind of CAFs. NAF: normal-associated fibroblasts; PT: primary tumor; LM: liver metastasis, n = 3 biologically independent experiments. G qRT-PCR and western blot assessed the knockdown efficiency of si-CD44 in CAFs. H, I Western blot analysis was conducted to evaluate HIF-1α and β-catenin protein expression in control (si-NC) and CD44 knockdown CAFs, with or without conditional medium from HCT116-HM (H) or LOVO-HM (I). J CAF cells were transfected with si-NC or si-CD44 and subsequently treated with conditioned medium from SPP1-overexpressing HCT116 or LoVo cells. The expression levels of β-catenin and HIF-1α were then assessed by western blot. K Western blot analysis was conducted to evaluate HIF-1α and β-catenin protein expression in control (si-NC) and CD44 knockdown CAFs, with or without rhSPP1 protein (1 µg/mL) treatment. L Nuclear-cytoplasmic fractionation was performed to assess the nuclear translocation of HIF-1α in control (si-NC) and CD44 knockdown CAFs, with or without treatment with rhSPP1 protein (1 µg/mL). Western blot experiments in (A, C, F-J) were repeated three times, the data are representative of three biologically independent experiments. All results are presented as mean ± SEM. P values were determined by two-tailed unpaired Student’s t test (C) and one-way ANOVA (B, E-G). ns, no significant difference, **P < 0.01, ***P < 0.001.
- Open Access
- 2 January 2026
- Published by American Association for Cancer Research (AACR)
Figure S3 from SPP1 Drives Colorectal Cancer Liver Metastasis and Immunotherapy Resistance by Stimulating CXCL12 Production in Cancer-Associated Fibroblasts
Figure S3 SPP1 positively correlates with CAF marker expression and promotes FAP expression. A Correlation analysis of SPP1 with CAF marker genes from TCGA data. B Brightfield and fluorescence images of PT-PDOs #1 and LM-PDO #1 stably expressing GFP-SPP1. Green fluorescence indicates SPP1 expression. Scale bar, 500 μm. C Supernatants from PDOs overexpressing SPP1 or Vector were collected at various time points to stimulate CAFs, followed by western blot analysis of FAP level, n = 3 biologically independent experiments. CM, Conditional Medium.
- 2 January 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S3 from SPP1 Drives Colorectal Cancer Liver Metastasis and Immunotherapy Resistance by Stimulating CXCL12 Production in Cancer-Associated Fibroblasts
Figure S3 SPP1 positively correlates with CAF marker expression and promotes FAP expression. A Correlation analysis of SPP1 with CAF marker genes from TCGA data. B Brightfield and fluorescence images of PT-PDOs #1 and LM-PDO #1 stably expressing GFP-SPP1. Green fluorescence indicates SPP1 expression. Scale bar, 500 μm. C Supernatants from PDOs overexpressing SPP1 or Vector were collected at various time points to stimulate CAFs, followed by western blot analysis of FAP level, n = 3 biologically independent experiments. CM, Conditional Medium.
- Open Access
- 2 January 2026
- Published by American Association for Cancer Research (AACR)
Figure S4 from SPP1 Drives Colorectal Cancer Liver Metastasis and Immunotherapy Resistance by Stimulating CXCL12 Production in Cancer-Associated Fibroblasts
Figure S4 CAF enhances SPP1-induced suppression of T-cell cytotoxicity. A Schematic representation of the tumor cell and T cell coculture system with or without CAFs. B, C After 24 hours of coculture with or without CAFs, propidium iodide staining was used to identify LoVo (B) or HCT116 (C) cells killed by T cells. Fluorescence microscopy assessed the effects of SPP1 overexpression on T-cell cytotoxicity, n = 3 biologically independent experiments. Scale bar, 100 μm. D Schematic representation of the tumor cell and T cell coculture system, with or without CAFs and SPP1 protein (1 µg/mL) treatment. E, F After 24 hours of coculture with or without CAFs, propidium iodide staining was used to identify LoVo (E) or HCT116 (F) cells killed by T cells. Fluorescence microscopy assessed the effects of SPP1 protein (1 µg/mL) treatment on T-cell cytotoxicity, n = 3 biologically independent experiments. Scale bar, 100 μm. G Schematic representation of the tumor cell and T cell coculture system, with or without CXCL12 protein (100 ng/mL) or CXCL12-neutralizing antibody (100 ng/mL) treatment. H, I After 24 hours of coculture, propidium iodide labeling identified LoVo and HCT116 cells killed by T cells. Fluorescence microscopy assessed the effects of CXCL12 protein (100 ng/mL) or CXCL12-neutralizing antibody (100 ng/mL) treatment on T-cell cytotoxicity, n = 3 biologically independent experiments. Scale bar, 100 μm. All results are presented as mean ± SEM. P values were determined by one-way ANOVA. ns, no significant difference, *P < 0.05, ***P < 0.001. PI, propidium iodide.
- 2 January 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S4 from SPP1 Drives Colorectal Cancer Liver Metastasis and Immunotherapy Resistance by Stimulating CXCL12 Production in Cancer-Associated Fibroblasts
Figure S4 CAF enhances SPP1-induced suppression of T-cell cytotoxicity. A Schematic representation of the tumor cell and T cell coculture system with or without CAFs. B, C After 24 hours of coculture with or without CAFs, propidium iodide staining was used to identify LoVo (B) or HCT116 (C) cells killed by T cells. Fluorescence microscopy assessed the effects of SPP1 overexpression on T-cell cytotoxicity, n = 3 biologically independent experiments. Scale bar, 100 μm. D Schematic representation of the tumor cell and T cell coculture system, with or without CAFs and SPP1 protein (1 µg/mL) treatment. E, F After 24 hours of coculture with or without CAFs, propidium iodide staining was used to identify LoVo (E) or HCT116 (F) cells killed by T cells. Fluorescence microscopy assessed the effects of SPP1 protein (1 µg/mL) treatment on T-cell cytotoxicity, n = 3 biologically independent experiments. Scale bar, 100 μm. G Schematic representation of the tumor cell and T cell coculture system, with or without CXCL12 protein (100 ng/mL) or CXCL12-neutralizing antibody (100 ng/mL) treatment. H, I After 24 hours of coculture, propidium iodide labeling identified LoVo and HCT116 cells killed by T cells. Fluorescence microscopy assessed the effects of CXCL12 protein (100 ng/mL) or CXCL12-neutralizing antibody (100 ng/mL) treatment on T-cell cytotoxicity, n = 3 biologically independent experiments. Scale bar, 100 μm. All results are presented as mean ± SEM. P values were determined by one-way ANOVA. ns, no significant difference, *P < 0.05, ***P < 0.001. PI, propidium iodide.
- Open Access
- 2 January 2026
- Published by American Association for Cancer Research (AACR)
Figure S7 from SPP1 Drives Colorectal Cancer Liver Metastasis and Immunotherapy Resistance by Stimulating CXCL12 Production in Cancer-Associated Fibroblasts
Figure S7 Tumor-derived SPP1 promotes the progression of CRLM and immunotherapy resistance independent of macrophages. A Flowchart of the intrasplenic injection model of liver metastasis in mice using OE-SPP1 or OE-vector MC38 cells. i.s.v., intrasplenic injection; i.p., intraperitoneal injection. Clo: Clodronate-liposomes. B Representative H&E staining of metastatic livers from C57BL/6J mice intrasplenically implanted with SPP1-overexpressing or vector-overexpressing MC38 cells, followed by treatment with anti-PD-1 antibody. Scale bar, 1 mm. C Quantification of liver weight and tumor burden in liver metastases from the indicated mouse groups (n = 5 per group), with tumor burden assessed by the tumor-to-liver area ratio in tissue sections. D Flow cytometric analysis of macrophage populations in liver metastases from the indicated mouse groups (n = 5 per group). Mac+ represents the control group, MacΔ represents the macrophage depletion group. E, F Flow cytometric analysis of IFN-γ+ CD8+ and GZMB+ CD8+ T cell populations in liver metastases from the indicated mouse groups (n = 5 per group). G, H Collagen content was evaluated by Masson’s trichrome staining, α-SMA expression levels were assessed via IHC analysis, and cell apoptosis was measured by TUNEL staining. Integrated Optical Density (IOD) was used for quantification in all assays (n = 5 per group). Scale bar = 40 μm. I Flow cytometry validated the engraftment of hCD45+ cell 7 days post implantation in each group of mice (n = 3/group). All results are presented as mean ± SEM. P values were determined by one-way ANOVA. ns, no significant difference, *P < 0.05, **P < 0.01, ***P < 0.001.
- 2 January 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S7 from SPP1 Drives Colorectal Cancer Liver Metastasis and Immunotherapy Resistance by Stimulating CXCL12 Production in Cancer-Associated Fibroblasts
Figure S7 Tumor-derived SPP1 promotes the progression of CRLM and immunotherapy resistance independent of macrophages. A Flowchart of the intrasplenic injection model of liver metastasis in mice using OE-SPP1 or OE-vector MC38 cells. i.s.v., intrasplenic injection; i.p., intraperitoneal injection. Clo: Clodronate-liposomes. B Representative H&E staining of metastatic livers from C57BL/6J mice intrasplenically implanted with SPP1-overexpressing or vector-overexpressing MC38 cells, followed by treatment with anti-PD-1 antibody. Scale bar, 1 mm. C Quantification of liver weight and tumor burden in liver metastases from the indicated mouse groups (n = 5 per group), with tumor burden assessed by the tumor-to-liver area ratio in tissue sections. D Flow cytometric analysis of macrophage populations in liver metastases from the indicated mouse groups (n = 5 per group). Mac+ represents the control group, MacΔ represents the macrophage depletion group. E, F Flow cytometric analysis of IFN-γ+ CD8+ and GZMB+ CD8+ T cell populations in liver metastases from the indicated mouse groups (n = 5 per group). G, H Collagen content was evaluated by Masson’s trichrome staining, α-SMA expression levels were assessed via IHC analysis, and cell apoptosis was measured by TUNEL staining. Integrated Optical Density (IOD) was used for quantification in all assays (n = 5 per group). Scale bar = 40 μm. I Flow cytometry validated the engraftment of hCD45+ cell 7 days post implantation in each group of mice (n = 3/group). All results are presented as mean ± SEM. P values were determined by one-way ANOVA. ns, no significant difference, *P < 0.05, **P < 0.01, ***P < 0.001.